| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) EA Eisenhauer, P Therasse, J Bogaerts, LH Schwartz, D Sargent, R Ford, ... European journal of cancer 45 (2), 228-247, 2009 | 28700 | 2009 |
| Prospective randomized trial of docetaxel versus best supportive care in patients with non–small-cell lung cancer previously treated with platinum-based chemotherapy FA Shepherd, J Dancey, R Ramlau, K Mattson, R Gralla, M O’Rourke, ... Journal of Clinical Oncology 18 (10), 2095-2103, 2000 | 2881 | 2000 |
| iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics L Seymour, J Bogaerts, A Perrone, R Ford, LH Schwartz, S Mandrekar, ... The Lancet Oncology 18 (3), e143-e152, 2017 | 2013 | 2017 |
| RECIST 1.1—Update and clarification: From the RECIST committee LH Schwartz, S Litière, E De Vries, R Ford, S Gwyther, S Mandrekar, ... European journal of cancer 62, 132-137, 2016 | 1551 | 2016 |
| Phase II trial of gefitinib in recurrent glioblastoma JN Rich, DA Reardon, T Peery, JM Dowell, JA Quinn, KL Penne, ... Journal of Clinical Oncology 22 (1), 133-142, 2004 | 873 | 2004 |
| Response assessment criteria for brain metastases: proposal from the RANO group NU Lin, EQ Lee, H Aoyama, IJ Barani, DP Barboriak, BG Baumert, ... The lancet oncology 16 (6), e270-e278, 2015 | 872 | 2015 |
| Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study E Galanis, JC Buckner, MJ Maurer, JI Kreisberg, K Ballman, J Boni, ... Journal of Clinical Oncology 23 (23), 5294-5304, 2005 | 839 | 2005 |
| Issues and progress with protein kinase inhibitors for cancer treatment J Dancey, EA Sausville Nature reviews Drug discovery 2 (4), 296-313, 2003 | 805 | 2003 |
| Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of … MJ Moore, J Hamm, J Dancey, PD Eisenberg, M Dagenais, A Fields, ... Journal of clinical oncology 21 (17), 3296-3302, 2003 | 474 | 2003 |
| Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme SM Chang, P Wen, T Cloughesy, H Greenberg, D Schiff, C Conrad, K Fink, ... Investigational new drugs 23, 357-361, 2005 | 473 | 2005 |
| mTOR signaling and drug development in cancer J Dancey Nature reviews Clinical oncology 7 (4), 209-219, 2010 | 449 | 2010 |
| Strategies for optimizing combinations of molecularly targeted anticancer agents JE Dancey, HX Chen Nature reviews Drug discovery 5 (8), 649-659, 2006 | 438 | 2006 |
| The genetic basis for cancer treatment decisions JE Dancey, PL Bedard, N Onetto, TJ Hudson Cell 148 (3), 409-420, 2012 | 416 | 2012 |
| Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma MB Thomas, R Chadha, K Glover, X Wang, J Morris, T Brown, A Rashid, ... Cancer 110 (5), 1059-1067, 2007 | 416 | 2007 |
| Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer KS Saini, S Loi, E de Azambuja, O Metzger-Filho, ML Saini, M Ignatiadis, ... Cancer treatment reviews 39 (8), 935-946, 2013 | 410 | 2013 |
| Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group AM Oza, L Elit, MS Tsao, S Kamel-Reid, J Biagi, DM Provencher, ... Journal of Clinical Oncology 29 (24), 3278-3285, 2011 | 390 | 2011 |
| A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas I Duran, J Kortmansky, D Singh, H Hirte, W Kocha, G Goss, L Le, A Oza, ... British journal of cancer 95 (9), 1148-1154, 2006 | 385 | 2006 |
| Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres JE Dancey, FA Shepherd, K Paul, KW Sniderman, S Houle, J Gabrys, ... Journal of nuclear medicine 41 (10), 1673-1681, 2000 | 368 | 2000 |
| A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer RK Ramanathan, CP Belani, DA Singh, M Tanaka, HJ Lenz, Y Yen, ... Cancer chemotherapy and pharmacology 64, 777-783, 2009 | 341 | 2009 |
| A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy JJ Raizer, LE Abrey, AB Lassman, SM Chang, KR Lamborn, JG Kuhn, ... Neuro-oncology 12 (1), 95-103, 2010 | 337 | 2010 |
